The year in cardiovascular medicine 2021: diabetes and metabolic disorders

Francesco Cosentino; Deepak L. Bhatt; Nikolaus Marx; Subodh Verma

doi:10.1093/eurheartj/ehab876

The year in cardiovascular medicine 2021: diabetes and metabolic disorders

Francesco Cosentino, Deepak L. Bhatt, Nikolaus Marx, Subodh Verma

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

Original language	English
Pages (from-to)	263-270
Number of pages	8
Journal	European Heart Journal
Volume	43
Issue number	4
DOIs	https://doi.org/10.1093/eurheartj/ehab876
State	Published - 21 Jan 2022
Externally published	Yes

Keywords

Aldosterone receptor antagonism
Diabetes mellitus
GLP-1 receptor agonists
Heart failure
Obesity
Omega-3 fatty acid mixtures
SGLT2 inhibitors

Access to Document

10.1093/eurheartj/ehab876

Cite this

@article{35e61484ed654aeeb3e9a4e8cfea054b,

title = "The year in cardiovascular medicine 2021: diabetes and metabolic disorders",

abstract = "In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.",

keywords = "Aldosterone receptor antagonism, Diabetes mellitus, GLP-1 receptor agonists, Heart failure, Obesity, Omega-3 fatty acid mixtures, SGLT2 inhibitors",

author = "Francesco Cosentino and Bhatt, {Deepak L.} and Nikolaus Marx and Subodh Verma",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = jan,

day = "21",

doi = "10.1093/eurheartj/ehab876",

language = "English",

volume = "43",

pages = "263--270",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - The year in cardiovascular medicine 2021

T2 - diabetes and metabolic disorders

AU - Cosentino, Francesco

AU - Bhatt, Deepak L.

AU - Marx, Nikolaus

AU - Verma, Subodh

N1 - Publisher Copyright: © The Author(s) 2022.

PY - 2022/1/21

Y1 - 2022/1/21

N2 - In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

AB - In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptiide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

KW - Aldosterone receptor antagonism

KW - Diabetes mellitus

KW - GLP-1 receptor agonists

KW - Heart failure

KW - Obesity

KW - Omega-3 fatty acid mixtures

KW - SGLT2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85123969472&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehab876

DO - 10.1093/eurheartj/ehab876

M3 - Article

C2 - 34974614

AN - SCOPUS:85123969472

SN - 0195-668X

VL - 43

SP - 263

EP - 270

JO - European Heart Journal

JF - European Heart Journal

IS - 4

ER -

The year in cardiovascular medicine 2021: diabetes and metabolic disorders

Abstract

Keywords

Access to Document

Fingerprint

Cite this